PharmaEngine
4162.TWO
1.70 USD
-0.01
-0.58%
p
Overview
Last close
1.70 usd
Market cap
244.80M usd
52 week high
3.23 usd
52 week low
1.63 usd
Target price
3.78 usd
Valuation
P/E
14.4385
Forward P/E
6.2735
Price/Sales
7.5689
Price/Book Value
1.5802
Enterprise Value
85.82M usd
EV/Revenue
2.6581
EV/EBITDA
4.1428
Key financials
Revenue TTM
32.29M usd
Gross Profit TTM
30.31M usd
EBITDA TTM
15.33M usd
Earnings per Share
0.12 usd
Dividend
0.06 usd
Total assets
170.54M usd
Net debt
N/A usd
About
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
- Symbol4162.TWO
- ExchangeTWO
- IsinTW0004162003
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CEOMr. Hong-Ren Wang Ph.D.
- HeadquarterTaipei
- Web sitehttps://www.pharmaengine.com
